Sign In
Buy IONS
$55.07
+0.580 (+1.06%)
At Close: Aug 04, 2026
FDA Accepts Ionis' (IONS) NDA for Rare Disease Drug Olezarsen
02:01pm, Wednesday, 26'th Jun 2024
The FDA grants priority review to Ionis' (IONS) filing seeking approval for olezarsen to treat adults with familial chylomicronemia syndrome. A final decision is expected in December 2024.
Ionis Pharmaceuticals (IONS) Soars 6.8%: Is Further Upside Left in the Stock?
07:30am, Tuesday, 25'th Jun 2024
Ionis Pharmaceuticals (IONS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be mo
Ionis announces olezarsen FCS New Drug Application accepted for Priority Review and enrollment in Phase 3 sHTG program completed
06:55am, Tuesday, 25'th Jun 2024
– Olezarsen PDUFA date set for December 19, 2024 for treatment of familial chylomicronemia syndrome – – Phase 3 enrollment completed in CORE, CORE2 and ESSENCE ev
Ionis (IONS) Expands Licensing Deal With Otsuka for HAE Drug
01:15pm, Wednesday, 19'th Jun 2024
Ionis (IONS) out-licenses the rights for its HAE drug to Otsuka in the Asia-Pacific region. The companies signed a similar deal last year granting Otsuka rights to market the drug in Europe.
Otsuka will be responsible for commercialization efforts for donidalorsen across both Asia Pacific and Europe Ionis plans to independently bring donidalorsen to U.S. patients, if approved CARLSBAD, Ca
Ionis to present at TD Cowen Genetic Medicines & RNA Summit
04:09pm, Monday, 17'th Jun 2024
CARLSBAD, Calif. , June 17, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in a fireside chat at the virtual TD Cowen Genetic Medicine
Donidalorsen delivered significant and sustained reductions in HAE attacks, with high levels of disease control and improvement in quality of life measures with monthly or every two-month dosing; cont
Ionis: Tough Run For Share Price Belies Multiple Reasons For Optimism
04:39pm, Tuesday, 28'th May 2024
Ionis Pharmaceuticals' Q1 2024 earnings showed a loss of $143m, a larger loss than the $87m in the previous year. The company has a healthy cash balance of $2.2bn and expects revenues of +$575m in 202
Ionis to hold donidalorsen Phase 3 data webcast
07:00am, Tuesday, 28'th May 2024
Webcast scheduled for Friday, May 31 at 8:00 a.m. Eastern Time CARLSBAD, Calif.
– Results across NEURO-TTRansform subgroups show consistent benefit in neuropathy impairment and improved quality of life, regardless of patient segmentation – CARLSBAD, Calif. , May 23, 2024 /PRN
Ionis (IONS), Biogen Down on Ending Development of ALS Drug
11:11am, Friday, 17'th May 2024
Ionis (IONS) and Biogen (BIIB) stop developing their experimental ALS drug after a phase I/II study failed to show improvement in patients.
Biogen and Ionis Pharma shares slide as they end development of ALS treatment
02:07pm, Thursday, 16'th May 2024
The stocks of Biogen Inc. and Ionis Pharmaceuticals Inc. were lower Thursday, after the partners said they were terminating development of a treatment for the fatal disease Amyotrophic Lateral Scleros
Biogen, Ionis to discontinue development of ALS drug
07:41am, Thursday, 16'th May 2024
Biogen and Ionis Pharmaceuticals said on Thursday they will terminate the development of their experimental treatment for amyotrophic lateral sclerosis (ALS) after failing to show improvement in patie
Ionis and Biogen Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis
07:30am, Thursday, 16'th May 2024
Development of BIIB105, an investigational antisense oligonucleotide for amyotrophic lateral sclerosis (ALS), will be discontinued based on data from the Phase 1/2 ALSpire study Biogen and Ionis cont
Ionis announces positive topline results from Phase 1/2a trial of ION582 for Angelman syndrome
07:00am, Thursday, 16'th May 2024
ION582 demonstrated consistent improvements across multiple functional domains in Angelman syndrome patients ION582 was safe and well tolerated at all dose levels Ionis plans to move ION582 into pivot
